Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Open-label, Two Cohorts, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

NCT06723691 is registered in ClinicalTrials.gov with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06723691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06723691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Open-label, Two Cohorts, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 18, 2024
Completion date
June 9, 2025
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes